Skip to main content
SpringerLink
Log in
Book cover

Treatment of Non-infectious Uveitis pp 67–84Cite as

Biologics Targeting Tumor Necrosis Factor

  • Chapter
  • First Online:

  • 387 Accesses

Abstract

Tumor necrosis factor (TNF) is a cytokine which is a key mediator of inflammation. Evidence from animal models of uveitis and observations on patients with uveitis provides strong support for the role of increased TNF activity in the pathogenesis of noninfectious uveitis, which is believed to be immune-mediated. Biologics that target TNF have been in use for the treatment of patients with uveitis since 2001. Five different anti-TNF biologics have been used in patients with chronic or recurrent uveitis refractory to nonbiologic agents. However, to date, only two of these agents, namely, infliximab and adalimumab, have a substantial amount of evidence supporting their clinical efficacy in noninfectious uveitis. Etanercept does not appear to be efficacious in uveitis and is not recommended for the treatment of uveitis. Golimumab and certolizumab currently only have a limited amount of data on their efficacy in treating uveitis, but could potentially be useful. Biologic TNF inhibitors appear to have a good safety profile in the short-term, but the long-term safety profile is not yet fully known. Additional drawbacks regarding the use of biologic TNF inhibitors for the treatment of uveitis include the lack of efficacy data from randomized controlled trials for specific entities of uveitis, high cost, the need for systemic administration, and the failure of some patients to achieve remission.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. De Vos AF, Van Haren MA, Verhagen C, Hoekzema R, Kijlstra A. Kinetics of intraocular tumor necrosis factor and interleukin-6 in endotoxin-induced uveitis in the rat. Invest Ophthalmol Vis Sci. 1994;35(3):1100–6.

    PubMed  Google Scholar 

  2. Santos LM, Marcos MC, Gallardo Galera JM, Gomez Vidal MA, Collantes EE, Ramirez CR, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33(5):251–5.

    Article  Google Scholar 

  3. Ozdamar Y, Berker N, Bahar G, Soykan E, Bicer T, Ozkan SS, et al. Inflammatory mediators and posterior segment involvement in ocular Behcet disease. Eur J Ophthalmol. 2009;19(6):998–1003.

    Article  PubMed  Google Scholar 

  4. Kopplin LJ, Shifera AS, Suhler EB, Lin P. Biological response modifiers in the treatment of noninfectious uveitis. Int Ophthalmol Clin. 2015;55(2):19–36.

    Article  PubMed  Google Scholar 

  5. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10(1):45–65.

    Article  CAS  PubMed  Google Scholar 

  6. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med. 1994;45:491–503.

    Article  CAS  PubMed  Google Scholar 

  7. Chu WM. Tumor necrosis factor. Cancer Lett. 2013;328(2):222–5.

    Article  CAS  PubMed  Google Scholar 

  8. Willermain F, Rosenbaum JT, Bodaghi B, Rosenzweig HL, Childers S, Behrend T, et al. Interplay between innate and adaptive immunity in the development of non-infectious uveitis. Prog Retin Eye Res. 2012;31(2):182–94.

    Article  CAS  PubMed  Google Scholar 

  9. Dick AD, Forrester JV, Liversidge J, Cope AP. The role of tumour necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res. 2004;23(6):617–37.

    Article  CAS  PubMed  Google Scholar 

  10. De Vos AF, Van Haren MA, Verhagen C, Hoekzema R, Kijlstra A. Tumour necrosis factor-induced uveitis in the Lewis rat is associated with intraocular interleukin 6 production. Exp Eye Res. 1995;60(2):199–207.

    Article  PubMed  Google Scholar 

  11. Rosenbaum JT, Howes EL Jr, Rubin RM, Samples JR. Ocular inflammatory effects of intravitreally-injected tumor necrosis factor. Am J Pathol. 1988;133(1):47–53.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM, et al. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum. 2001;45(3):252–7.

    Article  CAS  PubMed  Google Scholar 

  13. Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet’s disease. Lancet. 2001;358(9278):295–6.

    Article  CAS  PubMed  Google Scholar 

  14. Arayssi T, Hamra R, Homeidan F, Uthman I, Awwad ST, Mroue K, et al. The efficacy of a single dose of infliximab in the treatment of Behcet’s disease uveitis. Clin Exp Rheumatol. 2005;23(3):427.

    CAS  PubMed  Google Scholar 

  15. Mansour AM. Infliximab treatment of posterior uveitis. Ophthalmology. 2004;111(1):197–8.

    Article  PubMed  Google Scholar 

  16. itez-Del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E, Mendez-Fernandez R, Lopez-Abad C, Matilla M, et al. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab). Eye (Lond). 2005;19(8):841–5.

    Article  CAS  Google Scholar 

  17. Joseph A, Raj D, Dua HS, Powell PT, Lanyon PC, Powell RJ. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology. 2003;110(7):1449–53.

    Article  PubMed  Google Scholar 

  18. Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet’s disease: an open-label trial. Arthritis Rheum. 2005;52(8):2478–84.

    Article  CAS  PubMed  Google Scholar 

  19. Wechsler B, Sable-Fourtassou R, Bodaghi B, Huong DL, Cassoux N, Badelon I, et al. Infliximab in refractory uveitis due to Behcet’s disease. Clin Exp Rheumatol. 2004;22(4 Suppl 34):S14–6.

    CAS  PubMed  Google Scholar 

  20. Kruithof E, Kestelyn P, Elewaut C, Elewaut D, Van Den BF, Mielants H, et al. Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitis. Ann Rheum Dis. 2002;61(5):470.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. El-Shabrawi Y, Hermann J. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology. 2002;109(12):2342–6.

    Article  PubMed  Google Scholar 

  22. El-Shabrawi Y, Hermann J. Case series of selective anti-tumor necrosis factor alpha therapy using infliximab in patients with nonresponsive chronic HLA-B27-associated anterior uveitis: comment on the articles by Brandt et al. Arthritis Rheum. 2002;46(10):2821–2.

    Article  PubMed  Google Scholar 

  23. Kahn P, Weiss M, Imundo LF, Levy DM. Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology. 2006;113(5):860–4.

    Article  PubMed  Google Scholar 

  24. Rajaraman RT, Kimura Y, Li S, Haines K, Chu DS. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. 2006;113(2):308–14.

    Article  PubMed  Google Scholar 

  25. Murphy CC, Ayliffe WH, Booth A, Makanjuola D, Andrews PA, Jayne D. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology. 2004;111(2):352–6.

    Article  PubMed  Google Scholar 

  26. Mangge H, Heinzl B, Grubbauer HM, El-Shabrawi Y, Schauenstein K. Therapeutic experience with infliximab in a patient with polyarticular juvenile idiopathic arthritis and uveitis. Rheumatol Int. 2003;23(5):258–61.

    Article  PubMed  Google Scholar 

  27. Baughman RP, Bradley DA, Lower EE. Infliximab in chronic ocular inflammation. Int J Clin Pharmacol Ther. 2005;43(1):7–11.

    Article  CAS  PubMed  Google Scholar 

  28. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest. 2005;127(3):1064–71.

    Article  CAS  PubMed  Google Scholar 

  29. Pritchard C, Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis. 2004;63(3):318–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Fries W, Giofre MR, Catanoso M, Lo GR. Treatment of acute uveitis associated with Crohn’s disease and sacroileitis with infliximab. Am J Gastroenterol. 2002;97(2):499–500.

    Article  PubMed  Google Scholar 

  31. Ally MR, Veerappan GR, Koff JM. Treatment of recurrent Crohn’s uveitis with infliximab. Am J Gastroenterol. 2008;103(8):2150–1.

    Article  PubMed  Google Scholar 

  32. Rispo A, Scarpa R, Di GE, Cozzolino A, Lembo G, Atteno M, et al. Infliximab in the treatment of extra-intestinal manifestations of Crohn’s disease. Scand J Rheumatol. 2005;34(5):387–91.

    Article  CAS  PubMed  Google Scholar 

  33. Niccoli L, Nannini C, Benucci M, Chindamo D, Cassara E, Salvarani C, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet’s disease: a 24-month follow-up study. Rheumatology (Oxford). 2007;46(7):1161–4.

    Article  CAS  Google Scholar 

  34. Suhler EB, Smith JR, Giles TR, Lauer AK, Wertheim MS, Kurz DE, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol. 2009;127(6):819–22.

    CAS  PubMed  Google Scholar 

  35. Markomichelakis N, Delicha E, Masselos S, Sfikakis PP. Intravitreal infliximab for sight-threatening relapsing uveitis in Behcet disease: a pilot study in 15 patients. Am J Ophthalmol. 2012;154(3):534–41.

    Article  CAS  PubMed  Google Scholar 

  36. Giganti M, Beer PM, Lemanski N, Hartman C, Schartman J, Falk N. Adverse events after intravitreal infliximab (Remicade). Retina. 2010;30(1):71–80.

    Article  PubMed  Google Scholar 

  37. Wu L, Hernandez-Bogantes E, Roca JA, Arevalo JF, Barraza K, Lasave AF. Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group. Retina. 2011;31(2):298–303.

    Article  CAS  PubMed  Google Scholar 

  38. Correll CK, Bullock DR, Cafferty RM, Vehe RK. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis. Clin Rheumatol. 2018;37(2):549–53.

    Article  PubMed  Google Scholar 

  39. Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr. 2006;149(4):572–5.

    Article  CAS  PubMed  Google Scholar 

  40. Diaz-Llopis M, Salom D, Garcia-De-Vicuna C, Cordero-Coma M, Ortega G, Ortego N, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119(8):1575–81.

    Article  PubMed  Google Scholar 

  41. Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007;91(3):319–24.

    Article  PubMed  Google Scholar 

  42. Simonini G, Taddio A, Cattalini M, Caputo R, de LC, Parentin F, et al. Superior efficacy of adalimumab in treating childhood refractory chronic uveitis when used as first biologic modifier drug: adalimumab as starting anti-TNF-alpha therapy in childhood chronic uveitis. Pediatr Rheumatol Online J. 2013;11:16.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Tynjala P, Kotaniemi K, Lindahl P, Latva K, Aalto K, Honkanen V, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford). 2008;47(3):339–44.

    Article  CAS  Google Scholar 

  44. Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behcet’s disease. Eye (Lond). 2007;21(6):824–5.

    Article  CAS  Google Scholar 

  45. Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2012;250(5):713–20.

    Article  CAS  PubMed  Google Scholar 

  46. Suhler EB, Lowder CY, Goldstein DA, Giles T, Lauer AK, Kurz PA, et al. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial. Br J Ophthalmol. 2013;97(4):481–6.

    Article  PubMed  Google Scholar 

  47. Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Behcet disease. Ocul Immunol Inflamm. 2010;18(3):226–32.

    Article  CAS  PubMed  Google Scholar 

  48. Androudi S, Tsironi E, Kalogeropoulos C, Theodoridou A, Brazitikos P. Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology. 2010;117(8):1612–6.

    Article  PubMed  Google Scholar 

  49. Jaffe GJ, Dick AD, Brezin AP, Nguyen QD, Thorne JE, Kestelyn P, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–43.

    Article  CAS  PubMed  Google Scholar 

  50. Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388(10050):1183–92.

    Article  CAS  PubMed  Google Scholar 

  51. Suhler EB, Adán A, Brézin AP, Fortin E, Goto H, Jaffe GJ, Kaburaki T, Kramer M, Lim LL, Muccioli C, Nguyen QD, Van Calster J, Cimino L, Kron M, Song AP, Liu J, Pathai S, Camez A, Schlaen A, van Velthoven MEJ, Vitale AT, Zierhut M, Tari S, Dick AD. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology. 2018;125(7):1075–87.

    Article  PubMed  Google Scholar 

  52. Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, Hardwick B, Hickey H, Hughes D, Woo P, Benton D, Edelsten C, Beresford MW, SYCAMORE Study Group. Adalimumab plus methotrexate for uveitis in juvenile idiopathic arthritis. N Engl J Med. 2017;376(17):1637–46.

    Article  CAS  PubMed  Google Scholar 

  53. Cordero-Coma M, Salom D, Diaz-Llopis M, Lopez-Prats MJ, Calleja S. Golimumab for uveitis. Ophthalmology. 2011;118(9):1892–4.

    Article  PubMed  Google Scholar 

  54. Cordero-Coma M, Calvo-Rio V, Adan A, Blanco R, Alvarez-Castro C, Mesquida M, et al. Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience. Mediat Inflamm. 2014;2014:717598.

    Article  CAS  Google Scholar 

  55. Miserocchi E, Modorati G, Pontikaki I, Meroni PL, Gerloni V. Long-term treatment with golimumab for severe uveitis. Ocul Immunol Inflamm. 2014;22(2):90–5.

    Article  CAS  PubMed  Google Scholar 

  56. William M, Faez S, Papaliodis GN, Lobo AM. Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis. J Ophthalmic Inflamm Infect. 2012;2(4):231–3.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Miserocchi E, Modorati G, Pontikaki I, Meroni P, Gerloni V. Golimumab treatment for complicated uveitis. Clin Exp Rheumatol. 2013;31(2):320–1.

    PubMed  Google Scholar 

  58. Mesquida M, Victoria HM, Llorenc V, Pelegrin L, Espinosa G, Dick AD, et al. Behcet disease-associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm. 2013;21(2):160–2.

    Article  CAS  PubMed  Google Scholar 

  59. Faez S, Lobo AM, Sobrin L, Papaliodis GN. Treatment of seronegative spondyloarthropathy-associated uveitis with golimumab: retrospective case series. Clin Exp Ophthalmol. 2014;42(4):392–5.

    Article  PubMed  Google Scholar 

  60. Llorenc V, Mesquida M, Sainz de la MM, Blanco R, Calvo V, Maiz O, et al. Certolizumab Pegol, a new anti-TNF-alpha in the armamentarium against ocular inflammation. Ocul Immunol Inflamm. 2016;24(2):167–72.

    Google Scholar 

  61. Rudwaleit M, Rosenbaum JT, Landewe R, Marzo-Ortega H, Sieper J, van der HD, et al. Observed incidence of uveitis following Certolizumab Pegol treatment in patients with axial Spondyloarthritis. Arthritis Care Res (Hoboken). 2016;68(6):838–44.

    Article  CAS  Google Scholar 

  62. Tlucek PS, Stone DU. Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis. Cornea. 2012;31(1):90–1.

    Article  PubMed  Google Scholar 

  63. Moisseiev E, Shulman S. Certolizumab-induced uveitis: a case report and review of the literature. Case Rep Ophthalmol. 2014;5(1):54–9.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Reiff A, Takei S, Sadeghi S, Stout A, Shaham B, Bernstein B, et al. Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum. 2001;44(6):1411–5.

    Article  CAS  PubMed  Google Scholar 

  65. Tynjala P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66(4):548–50.

    Article  CAS  PubMed  Google Scholar 

  66. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 2005;52(8):2447–51.

    Article  CAS  PubMed  Google Scholar 

  67. Manzano RP, Carvounis PE, Albini TA, Holz ER. Etanercept monotherapy induces complete resolution of cystoid macular edema in a patient with intermediate uveitis. Retin Cases Brief Rep. 2007;1(4):261–3.

    Article  PubMed  Google Scholar 

  68. Foster CS, Tufail F, Waheed NK, Chu D, Miserocchi E, Baltatzis S, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol. 2003;121(4):437–40.

    Article  CAS  PubMed  Google Scholar 

  69. Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford). 2005;44(8):1008–11.

    Article  CAS  Google Scholar 

  70. Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53(1):18–23.

    Article  CAS  PubMed  Google Scholar 

  71. Shifera AS, Kopplin L, Lin P, Suhler EB. Drug-induced uveitis. Int Ophthalmol Clin. 2015;55(2):47–65.

    Article  PubMed  Google Scholar 

  72. Hawkins MJ, Dick AD, Lee RJ, Ramanan AV, Carreno E, Guly CM, et al. Managing juvenile idiopathic arthritis-associated uveitis. Surv Ophthalmol. 2016;61(2):197–210.

    Article  PubMed  Google Scholar 

  73. Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785–96.

    Article  PubMed  Google Scholar 

  74. Measurement of infliximab and anti-infliximab antibody levels can help distinguish maintenance versus loss of response. Gastroenterol Hepatol (NY). 2012;8(2):131–4.

    Google Scholar 

  75. Vogelzang EH, Kneepkens EL, Nurmohamed MT, van Kuijk AW, Rispens T, Wolbink G, et al. Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up. Ann Rheum Dis. 2014;73(12):2178–82.

    Article  CAS  PubMed  Google Scholar 

  76. Kempen JH, Daniel E, Dunn JP, Foster CS, Gangaputra S, Hanish A, et al. Overall and cancer related mortality among patients with ocular inflammation treated with immunosuppressive drugs: retrospective cohort study. BMJ. 2009;339:b2480.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  77. Kempen JH, Newcomb CW, Foster CS, Jabs DA, Levy-Clarke G, Rosenbaum JT, Nida Sen H, Suhler EB, Thorne JE, Bhatt NP, Buchanich JM. Risk of overall and cancer mortality after immunosuppression of patients with non-infectious ocular inflammatory diseases. Invest Ophthalmol Vis Sci. 2019;60:ARVO E-Abstract 3854.

    Google Scholar 

  78. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275–85.

    Article  CAS  PubMed  Google Scholar 

  79. Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3):529–35.

    Article  CAS  PubMed  Google Scholar 

  80. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken ). 2016;68(1):1–25.

    Article  Google Scholar 

  81. Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED. T-cell non-Hodgkin’s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013;108(1):99–105.

    Article  CAS  PubMed  Google Scholar 

  82. Tong D, Manolios N, Howe G, Spencer D. New onset sarcoid-like granulomatosis developing during anti-TNF therapy: an under-recognised complication. Intern Med J. 2012;42(1):89–94.

    Article  CAS  PubMed  Google Scholar 

  83. Famenini S, Wu JJ. Infliximab-induced psoriasis in treatment of Crohn’s disease-associated ankylosing spondylitis: case report and review of 142 cases. J Drugs Dermatol. 2013;12(8):939–43.

    CAS  PubMed  Google Scholar 

  84. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44(12):2862–9.

    Article  CAS  PubMed  Google Scholar 

  85. Foroozan R, Buono LM, Sergott RC, Savino PJ. Retrobulbar optic neuritis associated with infliximab. Arch Ophthalmol. 2002;120(7):985–7.

    PubMed  Google Scholar 

  86. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken ). 2012;64(5):625–39.

    Article  CAS  Google Scholar 

Download references

Acknowledgments

LJK has served as a coinvestigator in clinical trials sponsored by AbbVie, Bristol-Myers-Squibb, Genentech, pSivida, and the National Eye Institute and was also supported by institutional grants to the Casey Eye Institute from the National Eye Institute and Research to Prevent Blindness. AS is supported by a Mallinckrodt Foundation Research Fellowship Award. In addition, AS has participated as a coinvestigator in clinical trials sponsored by AbbVie, Bristol-Myers-Squibb, pSivida, and Genentech, the National Eye Institute, University of Pennsylvania, Research to Prevent Blindness, and Allergan.

Author information

Authors and Affiliations

  1. Department of Ophthalmology and Visual Sciences, University of Wisconsin – Madison, Madison, WI, USA

    Laura J. Kopplin

  2. Division of Ocular Immunology, Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA

    Amde Selassie Shifera

Authors
  1. Laura J. Kopplin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amde Selassie Shifera
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Oregon Health and Science University, Casey Eye Institute, Portland, OR, USA

    Phoebe Lin

  2. Oregon Health and Science University, OHSU-PSU School of Public Health, Portland Veterans Administration Medical Center, Portland, OR, USA

    Eric Suhler

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kopplin, L.J., Shifera, A.S. (2019). Biologics Targeting Tumor Necrosis Factor. In: Lin, P., Suhler, E. (eds) Treatment of Non-infectious Uveitis. Springer, Cham. https://doi.org/10.1007/978-3-030-22827-9_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-22827-9_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-22825-5

  • Online ISBN: 978-3-030-22827-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation